Diamyd Medical AB (publ) Share Price Nasdaq Stockholm
Equities
SE0005162880
Biotechnology & Medical Research
Sales 2024 * | 3M 274K 21.85M | Sales 2025 * | 3M 274K 21.85M | Capitalization | 1.13B 103M 8.22B |
---|---|---|---|---|---|
Net income 2024 * | -133M -12.15M -968M | Net income 2025 * | -165M -15.08M -1.2B | EV / Sales 2024 * | 330 x |
Net cash position 2024 * | 139M 12.7M 1.01B | Net cash position 2025 * | 30M 2.74M 218M | EV / Sales 2025 * | 366 x |
P/E ratio 2024 * |
-8.27
x | P/E ratio 2025 * |
-6.67
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 72.91% |
Latest transcript on Diamyd Medical AB (publ)
Managers | Title | Age | Since |
---|---|---|---|
Ulf Hannelius
CEO | Chief Executive Officer | 49 | 09/04/16 |
Founder | 83 | 31/12/95 | |
Anna Styrud
DFI | Director of Finance/CFO | 63 | 31/12/09 |
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | 83 | 31/12/95 | |
Director/Board Member | 63 | 31/12/11 | |
Director/Board Member | 52 | 27/04/21 |
1st Jan change | Capi. | |
---|---|---|
-2.63% | 103B | |
+1.62% | 95.28B | |
+1.46% | 22.15B | |
-16.67% | 21.02B | |
-8.58% | 18.15B | |
-38.74% | 16.73B | |
-13.21% | 16.05B | |
+5.41% | 13.68B | |
+33.57% | 12.17B |